Extended Paxlovid Shows No Benefit Over Placebo for Long COVID in 959-Patient RECOVER-VITAL RCT
A large NIH-funded RCT demonstrated that extended Paxlovid does not alleviate long COVID symptoms, undermining viral-persistence treatment strategies and redirecting research toward heterogeneous mechanisms. The double-blind design strengthens causal inference but leaves open questions about biomarker-defined subgroups.
The RECOVER-VITAL trial randomized 959 adults with long COVID at 69 U.S. sites to three masked regimens: full-dose Paxlovid for 25 days, 15 days active drug plus ritonavir placebo, or full placebo. Participants self-reported symptoms via validated scales at multiple time points through six months, with primary endpoints focused on change within prespecified symptom domains.
No arm showed statistically or clinically meaningful separation from placebo on any primary symptom measure. The longer regimen was safe, yet the null result directly challenges the hypothesis that persistent SARS-CoV-2 replication is a dominant, treatable driver in unselected long COVID populations.
This finding converges with observational data indicating immune and vascular mechanisms predominate over ongoing viral replication. It narrows the therapeutic window for antivirals and accelerates the RECOVER platform toward immunomodulatory and rehabilitation interventions already under way.
Next trials must embed biomarker stratification at enrollment to test whether viral-persistence subgroups exist and respond to antivirals, a design element absent from RECOVER-VITAL.
VITALIS: At least two RECOVER platform trials of non-antiviral interventions will meet their primary symptom endpoint within 18 months.
Sources (2)
- [1]Primary Source(https://doi.org/10.1016/S1473-3099(26)00406-8)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMra2402819)